LitAlert ~~ GeneLit.com

    • Ovarian and breast cancer risks associated with pathogenic variants in RAD51C and RAD51D.
    • Yang X, Song H, Leslie G, Engel C, Hahnen E, Auber B, Horváth J, Kast K, Niederacher D, Turnbull C, Houlston R, Hanson H, Loveday C, Dolinsky JS, LaDuca H, Ramus SJ, Menon U, Rosenthal AN, Jacobs I, Gayther SA, Dicks E, Nevanlinna H, Aittomäki K, Pelttari LM, Ehrencrona H, Borg Å, Kvist A, Rivera B, Hansen TVO, Djursby M, Lee A, Dennis J, Bowtell DD, Traficante N, Diez O, Balmaña J, Gruber SB, Chenevix-Trench G; kConFab Investigators, Jensen A, Kjær SK, Høgdall E, Castéra L, Garber J, Janavicius R, Osorio A, Golmard L, Vega A, Couch FJ, Robson M, Gronwald J, Domchek SM, Culver JO, de la Hoya M, Easton DF, Foulkes WD, Tischkowitz M, Meindl A, Schmutzler RK, Pharoah PDP, Antoniou AC.
    • J Natl Cancer Inst. 2020 Feb 28. pii: djaa030. doi: 10.1093/jnci/djaa030. [Epub ahead of print]
    • Predictors of genetic beliefs toward cancer risk perceptions among adults in the United States: Implications for prevention or early detection.
    • McKinney LP, Gerbi GB, Caplan LS, Claridy MD, Rivers BM.
    • J Genet Couns. 2020 Feb 27. doi: 10.1002/jgc4.1228. [Epub ahead of print]
    • Next generation sequencing of BRCA genes in glioblastoma multiform Egyptian patients: a pilot study.
    • Nageeb AM, Mohamed MM, Ezz El Arab LR, Khalifa MK, Swellam M.
    • Arch Physiol Biochem. 2020 Feb 26:1-9. doi: 10.1080/13813455.2020.1729814. [Epub ahead of print]
    • Frequency of BRCA1 and BRCA2 Mutations in Individuals with Breast and Ovarian Cancer in a Chinese Hakka Population Using Next-Generation Sequencing.
    • Wu H, Wang Q, Guo X, Liu Q, Zhang Q, Huang Q, Yu Z.
    • Hum Hered. 2020 Feb 26:1-10. doi: 10.1159/000505268. [Epub ahead of print]
    • When to break the news and whose responsibility is it? A cross-sectional qualitative study of health professionals' views regarding disclosure of BRCA genetic cancer risk.
    • Young AL, Butow PN, Tucker KM, Wakefield CE, Healey E, Williams R.
    • BMJ Open. 2020 Feb 25;10(2):e033127. doi: 10.1136/bmjopen-2019-033127.
    • Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells.
    • Burgess BT, Anderson AM, McCorkle JR, Wu J, Ueland FR, Kolesar JM.
    • Diagnostics (Basel). 2020 Feb 22;10(2). pii: E121. doi: 10.3390/diagnostics10020121.
    • BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study.
    • Kosaka Y, Yamamoto Y, Tanino H, Nishimiya H, Yamamoto-Ibusuki M, Hirota Y, Iwase H, Nakamura S, Akashi-Tanaka S.
    • Diagnostics (Basel). 2020 Feb 21;10(2). pii: E119. doi: 10.3390/diagnostics10020119.
    • Do Preferred Risk Formats Lead to Better Understanding? A Multicenter Controlled Trial on Communicating Familial Breast Cancer Risks Using Different Risk Formats.
    • Henneman L, van Asperen CJ, Oosterwijk JC, Menko FH, Claassen L, Timmermans DR.
    • Patient Prefer Adherence. 2020 Feb 19;14:333-342. doi: 10.2147/PPA.S232941. eCollection 2020.
    • Polymorphisms and rare variants identified by next-generation sequencing confer risk for lung cancer in han Chinese population.
    • Li X, Liu J, Wang K, Zhou J, Zhang H, Zhang M, Shi Y.
    • Pathol Res Pract. 2020 Feb 13:152873. doi: 10.1016/j.prp.2020.152873. [Epub ahead of print]
    • Personalized Treatment Approach to Metastatic Castration-Resistant Prostate Cancer with BRCA2 and PTEN Mutations: A Case Report.
    • Julka PK, Verma A, Gupta K.
    • Case Rep Oncol. 2020 Feb 4;13(1):55-61. doi: 10.1159/000505182. eCollection 2020 Jan-Apr.
    • Analysis of Heterozygous BRCA1 5382ins Founder Mutation in a Cohort of Egyptian Breast Cancer Female Patients Using Pyrosequencing Technique.
    • Gomaa Mogahed SH, Hamed YS, Ibrahim Moursy YE, Mahomoud Saied MH.
    • Asian Pac J Cancer Prev. 2020 Feb 1;21(2):431-438. doi: 10.31557/APJCP.2020.21.2.431.